Immunotherapy Clinical Trials in Fuzhou, Fujian
8 recruitingFuzhou, Fujian, China
Showing 1–8 of 8 trials
Recruiting
Phase 1
Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy
Acute Myeloid LeukemiaMaintenance TherapyPersonalized Active Immunotherapy
Fujian Medical University Union Hospital90 enrolled1 locationNCT07551037
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting
Phase 2
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
Advanced Colorectal CarcinomaImmunotherapy
Fudan University208 enrolled10 locationsNCT06521866
Recruiting
Phase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell CarcinomaImmunotherapyBiomarkers
Fujian Medical University Union Hospital48 enrolled1 locationNCT06510660
Recruiting
Phase 3
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Urinary Bladder NeoplasmsTreatment OutcomeImmunotherapy, Active+3 more
Fujian Medical University Union Hospital76 enrolled1 locationNCT06441110
Recruiting
Phase 2Phase 3
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Immunotherapy Gastrict Cancer
Fujian Cancer Hospital130 enrolled1 locationNCT05699655
Recruiting
Phase 2
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Immunotherapy Esophagus Cancer
Fuzhou General Hospital93 enrolled1 locationNCT05515315